Current Research in Triple-Negative Breast Cancer
Richard S. Finn, MD, discusses current research in triple-negative breast cancer
Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses current research in triple-negative breast cancer (TNBC).
Clinical Pearls:
- TNBC is an area of unmet need and is defined by the absence of a druggable target
- Researchers have studied Src inhibition and PARP inhibition in this space
- A new PARP inhibitor, BMN 673, looks particularly potent forBRCA-mutated breast cancer
- Patients withBRCA-mutated breast cancer are often triple negative
- There is still a need to better understand the biology of TNBC in order to bring the right drugs to these patients
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Dato-DXd Shows Promise as a More Tolerable ADC in HER2-Negative mBC
July 22nd 2024During a Case-Based Roundtable® event, Igor Makhlin, MD, discussed with participants their impressions of datopotamab deruxtecan as therapy for patients with HR-positive, HER2-negative breast cancer, and the sequential use of multiple antibody-drug conjugates.
Read More
